MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

3.950 +0.180 (+4.77%)
Streaming Delayed Price Updated: 2:00 PM EDT, Jul 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 312,044
Open 3.780
Bid (Size) 3.940 (1,500)
Ask (Size) 3.960 (1,100)
Prev. Close 3.770
Today's Range 3.690 - 4.020
52wk Range 1.850 - 6.600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+4.8%
+4.8%
1 Month
+16.2%
+16.2%
3 Month
+5.9%
+5.9%
6 Month
-0.5%
-0.5%
1 Year
+53.1%
+53.1%

More News

Read More
News headline image
SAB Biotherapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage ↗
Via Chartmill
News headline image
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
From Emergent BioSolutions
Via GlobeNewswire
News headline image
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is SAB Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, SAB Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does SAB Biotherapeutics, Inc. - Common Stock trade on?
SAB Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for SAB Biotherapeutics, Inc. - Common Stock?
The ticker symbol for SAB Biotherapeutics, Inc. - Common Stock is SABS on the Nasdaq Stock Market
What is the current price of SAB Biotherapeutics, Inc. - Common Stock?
The current price of SAB Biotherapeutics, Inc. - Common Stock is 3.950
When was SAB Biotherapeutics, Inc. - Common Stock last traded?
The last trade of SAB Biotherapeutics, Inc. - Common Stock was at 07/09/26 02:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story